We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Olatinib is a novel JAK inhibitor that also inhibits the function of JAK1 dependent cytokines in some anti allergic, inflammatory, and itch responses. Research has confirmed that experimental animals (dogs) taking oral doses of 0.4-0.6mg/kg twice a day are safe and effective in treating itching caused by atopic dermatitis, and exhibit better therapeutic effects than oral corticosteroids such as prednisolone. During treatment, olatinib can alleviate itching within 24 hours, and over 70% of experimental animals experienced a reduction of over 50% in itching on the 7th day. Currently, Olatinib has been approved by the US FDA in 2013 to control itching and atopic dermatitis caused by canine allergic dermatitis. However, although Olatinib has a good therapeutic effect on allergic skin diseases in pet dogs, its scope of action is narrow. On the one hand, it has little effect on cytokines that do not participate in activating JAK1. On the other hand, its effect on allergic reactions ultimately only manifests in inhibiting degranulation of mast cells, i.e. the release of allergic mediators. It cannot directly block the binding of allergic mediators to related receptors, nor can it fundamentally block the occurrence and development of allergic skin diseases
One year of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
![PHENYLALLYLCHLORO-[1,3-BIS(DIISOPROPYLPHENYL)IMIDAZOLE-2-YLIDENE]PALLADIUM(II)](https://eimg.pharmasources.com/image/product/20240418/3318af4d7e88b72529dfcc65073f71f2jpg!145)
